Application for production of 1.1 new hypoglycemic drug of Hengrui medicine

1.1 class 1 new drug regolitine is applied for production, and its long-term income is expected to exceed 1 billion yuan After apatinib and 19K, the class 1.1 new oral hypoglycemic drug regolitine of Hengrui pharmaceutical recently applied for production to the State Food and drug administration Regolitine is a new generation of DPP4 inhibitor, which has better efficacy than metformin and sulfonylurea Phase II clinical is no less than mosadon's siggliptine, with better safety The world's first DPP4 inhibitor, genovir (cigliptin phosphate tablets), was listed in 2006, with a sales volume of 4.4 billion US dollars in 2013, a sample hospital revenue of 43 million yuan in China in 2014, and an estimated terminal revenue of 200 million yuan Considering that the daily medication amount of siggliptin is not less than that of conventional insulin and needs to be paid for at one's own expense, which is much higher than that of similar oral drugs, 200 million yuan only reflects the high-end demand of diabetic patients, the market space is far from open, and it is still in the stage of patient education and market introduction The same kind of drugs are only available in China It is expected that regolitine will still have a good competition pattern and market space after it goes on the market Referring to the oral acarbose, which has entered the mature stage, it is expected that the long-term income will not be less than 1 billion yuan Hengrui diabetes pipeline has strong strength and will be no less important in the future than that of tumor in the face of the growing domestic demand for diabetes Hengrui pharmaceutical has a comprehensive pipeline for diabetes research and development, with DPP4, sglt-2 henggelijing, GPR40 agonist furoglitazone, long-acting insulin ins061 and other new drugs, as well as oral drugs and biological agents The core of the R & D team comes from Lilly pharmaceutical, one of the three diabetes giants With strong strength, Hengrui is expected to be one of the top diabetes enterprises in China CDE new drug approval is expected to speed up Innovative drug driven companies benefit from the fact that the SFDA started to increase the number of new drug reviewers last year, raise the cost and threshold of review, give priority to the review of class 1 innovative drugs, and the efficiency of new drug approval is expected to accelerate As a domestic innovative drug driven enterprise, Hengrui Pharmaceutical Co., Ltd has more than 100 R & D projects, including class 1 chemical new drugs such as famitinib, heavy first generic drugs such as fondagangui, and new immunotumor drugs such as PD-1 As an innovative drug driven enterprise, the approval and acceleration company has benefited significantly The company has formed a good situation of "generic + innovative + international" three-wheel drive We expect EPS to be 1.36/1.78/2.31 yuan in 2015-17, with more recent stock price adjustments, maintaining the "buy" rating The risk indicates the risk of price reduction of anticancer drugs such as oxaliplatin, the risk of R & D of new drugs such as 19K, and the risk of unstable orders of export products such as cyclophosphamide.